EGFR and lung adenocarcinoma: Furmonertinib, an EGFR-targeted drug, and its bioactive metabolite AST5902 were tested on A549 and H1975 cell line-based 3D LC models, as A549 is an EGFR wildtype lung adenocarcinoma cell while H1975 is an EGFR mutant one.